- Fulcrum Therapeutics (FULC, Financial) grants 96,800 stock options to new employees.
- Stock options have an exercise price of $2.72, matching the April 7, 2025 closing price.
- Options are subject to a ten-year term with a four-year vesting schedule.
Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company dedicated to the development of small molecules for rare genetic diseases, has announced the granting of stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The company has issued an aggregate of 96,800 stock options with an exercise price of $2.72 per share, which corresponds with the closing price of Fulcrum’s common stock on April 7, 2025.
The stock options awarded to the new employees will have a ten-year term. The vesting schedule is structured such that 25% of the options will vest on the first anniversary of the employee's start date. Thereafter, 6.25% of the shares will vest quarterly over the next three years, contingent upon the continued employment with Fulcrum Therapeutics.
Fulcrum Therapeutics continues to focus on developing innovative therapies for patients with genetically defined rare diseases, utilizing its proprietary technology to target gene expression. For more information about Fulcrum Therapeutics, please visit their official website or follow them on social media platforms such as Twitter/X and LinkedIn.
